EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSCJAG00000009078
Gene Symbol: KCNJ5
3 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSCJAG00000015327
Gene Symbol: KCNK2
5 Cross references
284 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSCJAG00000052158
Gene Symbol: KCNK3
5 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSCJAG00000086842
Gene Symbol: KCNK9
5 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSCJAG00000068399
Gene Symbol: KCNA5
3 Cross references
170 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSCJAG00000013456
Gene Symbol: KCND3
5 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSCJAG00000020150
Gene Symbol: KCNH2
5 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSCJAG00000010184
Gene Symbol: KCNQ2
5 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSCJAG00000004480
Gene Symbol: KCNQ3
5 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSCJAG00000009916
Gene Symbol: KCNQ5
5 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 1

Ensembl ID : ENSCJAG00000014387
Gene Symbol: PSEN1
5 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 2

Ensembl ID : ENSCJAG00000012908
Gene Symbol: PSEN2
5 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).